menu
    • menu
    [{"orgOrder":0,"company":"DMK Pharmaceuticals","sponsor":"Adamis Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Merger","leadProduct":"DPI-125","moa":"Kappa\/Mu\/delta-Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"DMK Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DMK Pharmaceuticals \/ Adamis Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"DMK Pharmaceuticals \/ Adamis Pharmaceuticals"},{"orgOrder":0,"company":"DMK Pharmaceuticals","sponsor":"Adamis Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Merger","leadProduct":"DPI-125","moa":"Kappa\/Mu\/delta-Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"DMK Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DMK Pharmaceuticals \/ Adamis Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"DMK Pharmaceuticals \/ Adamis Pharmaceuticals"},{"orgOrder":0,"company":"DMK Pharmaceuticals","sponsor":"ZMI Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Acquisition","leadProduct":"Naloxone Hydrochloride","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"DMK Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"DMK Pharmaceuticals \/ ZMI Pharma","highestDevelopmentStatusID":"15","companyTruncated":"DMK Pharmaceuticals \/ ZMI Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by DMK Pharmaceuticals

    Menu

    DMK Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            DMK Pharmaceuticals

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed

                            DMK Pharmaceuticals

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Naloxone Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Approved FDF

                            Sponsor : ZMI Pharma

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            ZMI Management Acquires ZIMHI™ from DMK Pharmaceuticals, Partners with FFF

                            Details : Zimhi (naloxone HCl Injection) is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, including fentanyl poisoning.

                            Product Name : Zimhi

                            Product Type : Controlled Substance

                            Upfront Cash : Undisclosed

                            June 20, 2024

                            Lead Product(s) : Naloxone Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Approved FDF

                            Sponsor : ZMI Pharma

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            DMK Pharmaceuticals

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed

                            DMK Pharmaceuticals

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DPI-125

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : Adamis Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Adamis Pharmaceuticals Announces Closing of the Merger with DMK Pharmaceuticals

                            Details : Through the merger, Adamis will acquire DMK, including its library of approximately 750 small molecule neuropeptide analogues and on-going government funding for its development programs including DPI-125, being studied as a potential novel treatment for...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            May 25, 2023

                            Lead Product(s) : DPI-125

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : Adamis Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            DMK Pharmaceuticals

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed

                            DMK Pharmaceuticals

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DPI-125

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : Adamis Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Adamis Pharmaceuticals and DMK Pharmaceuticals Announce Agreement and Plan of Merger

                            Details : Through the merger, Adamis will acquire DMK, including its library of approximately 750 small molecule neuropeptide analogues and on-going government funding for its development programs including DPI-125, being studied as a potential novel treatment for...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            February 27, 2023

                            Lead Product(s) : DPI-125

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : Adamis Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth